GA-Alliance

Healthcare & Life Sciences

GA-Alliance

We offer specialised legal advice in the health and life sciences sector, supporting pharmaceutical companies, biotechnology companies, medical research institutes and healthcare professionals.

Our team provides a full range of legal services to meet industry-specific needs, including:

Healthcare Regulation: Advice on national and international regulations in the healthcare sector, including regulations on the production and marketing of pharmaceuticals and medical devices.

Intellectual Property: Patent, trademark and copyright protection, including the management and defence of trademark and patent portfolios of pharmaceutical companies.

Contracts: Negotiation and drafting of commercial contracts in the healthcare sector, including licensing agreements, research and development collaboration, supply and distribution agreements.

Compliance: Assessment and implementation of compliance programmes, as well as the management of legal issues relating to privacy and data security.

Our professionals have a deep understanding of the unique challenges of the industry and are committed to providing high-quality legal advice to support our clients’ success and growth.

Our experts

VIEW MORE

Caricamento..

Insights

GA-Alliance

News

Lahore, Jan 30 2026

GA-Alliance lands in Pakistan
Press release

GA-Alliance lands in Pakistan: strategic partnership signed with Axis Law Chambers

MILAN – 29 January 2026

GA-Alliance, a global legal and tax firm with more than 2,600 professionals in 80 countries, announces its entry into the Pakistani market. The strategic partnership with Axis Law Chambers, a leading full‑service law firm in the region, marks a further expansion of GA‑Alliance’s network, which today covers geographies that generate nearly 90% of global GDP.

The agreement strengthens GA‑Alliance’s commitment to its “one‑stop‑shop” strategy. By integrating local expertise with the highest global standards, the Alliance offers clients a single, efficient access point for all legal and tax needs. This model removes the complexities of managing multiple advisers across different jurisdictions, delivering a coordinated and seamless experience that prioritizes clarity and business growth.

Axis Law Chambers brings to the Alliance a reputation for excellence, particularly in high‑value cross‑border mandates and advice on complex regulatory matters. Regularly listed by Chambers and Partners and The Legal 500, Axis Law stands out for its transactional work in corporate matters, mergers and acquisitions (M&A), employment law, intellectual property, foreign investment, public‑private partnerships, corporate governance, antitrust, tax, data protection and sectoral compliance. The firm advises clients in key industries such as energy, oil & gas, mining, healthcare, telecommunications, automotive, financial services, defense, retail, manufacturing, agriculture, media, IT, logistics, real estate and non‑profit organizations.

Axis Law also boasts one of Pakistan’s most authoritative dispute resolution practices, including litigation and international arbitration, with solid experience in proceedings before ICSID (International Centre for Settlement of Investment Disputes, based in Washington, D.C., and part of the World Bank), ICC (International Chamber of Commerce, based in Paris) and LCIA (London Court of International Arbitration, based in London). This depth of expertise ensures GA‑Alliance clients receive top‑level support in the world’s fifth most populous country, one of the most dynamic economies in Asia.

Francesco Sciaudone, Managing Partner of GA‑Alliance, emphasized the strategic importance of the operation: “Our entry into Pakistan through the partnership with Axis Law Chambers is another step that strengthens our global growth path. At GA‑Alliance, the goal is to simplify complexity for our clients. By extending our ‘one‑stop‑shop’ model to an outstanding Pakistani firm, we are increasingly able to offer our clients the ability to operate with confidence in a very large number of markets worldwide. We are not only expanding our geographic presence; we are enhancing a sophisticated ecosystem where international best practices and precision meet local market leadership to meet clients’ needs in a simple, direct and highly efficient way.”


About GA‑Alliance

With more than 2,600 professionals in 80 countries, GA‑Alliance is a global legal and tax firm with deep European roots, combining a strong legal tradition with a broad international presence. Founded on principles of excellence and innovation, GA‑Alliance offers integrated, multidisciplinary expertise and positions itself as a strategic partner to promote sustainable growth in an ever‑evolving regulatory environment.


About Axis Law Chambers

Axis Law Chambers is a leading Pakistani law firm recognized for excellence in corporate and transactional advice and in resolving commercial disputes. With a team of over 30 professionals and seven partners, the firm assists national and multinational clients in high‑impact transactions, regulatory compliance and complex dispute resolution matters, including international arbitrations.

GA-Alliance

Knowledge Management

Jul 23 2024

Eu Alert - Life Sciences

This newsletter provides a selection of opinions and analysis from our EU legal experts on interesting policy developments, recent case law and new regulatory directions of major industry practices. It is released biweekly and covers areas such as: Competition Law, Sanctions, Trade, Energy, Finance, EU funds, Data IP and Privacy, Life Sciences, Transport and Court of Justice of the European Union news.

The aim is to provide an up–to–date tool for quick and easy consultation on the most current and important topics at EU level.


EUROPEAN COMMISSION (EC)

The European Commission authorizes the first-ever vaccine against Chikungunya virus (28.06.2024) – The European Commission has authorised the first-ever vaccine against Chikungunya virus - a disease transmitted by infected mosquitoes. The EU authorisation of the Chikungunya vaccine is intended for adults over 18 years of age. It was unanimously endorsed by Member States following a stringent assessment by the European Medicines Agency (EMA). It is up to national authorities in each Member State to decide who will have access to the vaccine, taking into account the national situation and risk status.


EUROPEAN MEDICINES AGENCY (EMA)

The European Medicines Agency recommends Winrevair to treat adult patients with pulmonary arterial hypertension (28.06.2024) – The European Medicines Agency’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity The opinion will be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.

The European Medicines Agency recommends Eurneffyo for emergency treatment against allergic reactions (28.06.2024) – The European Medicines Agency’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Eurneffy (epinephrine), the first medicine to be taken through the nose for the emergency treatment of allergic reactions (anaphylaxis).The opinion will be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.

The European Medicines Agency recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna (28.06.2024) – The European Medicines Agency has concluded its review of the medicine Ocaliva (obeticholic acid) and has recommended that the medicine’s marketing authorisation be revoked, because its benefits are no longer considered to outweigh its risks. Ocaliva is used to treat adults with primary biliary cholangitis (PBC), an autoimmune condition that causes gradual destruction of the bile ducts in the liver, which can lead to liver failure and increase the risk of liver cancer.

The European Medicines Agency recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna (28.06.2024) – The European Medicines Agency has recommended not renewing the conditional marketing authorisation for Translarna (ataluren), a medicine for treating patients with Duchenne muscular dystrophy. Translarna is used in patients whose disease is caused by a type of genetic defect called a ‘nonsense mutation’ in the dystrophin gene and who are able to walk.

GA-Alliance

Knowledge Management

Jun 26 2024

EU Alert - Life Sciences

This newsletter provides a selection of opinions and analysis from our EU legal experts on interesting policy developments, recent case law and new regulatory directions of major industry practices. It is released biweekly and covers areas such as: Competition Law, Sanctions, Trade, Energy, Finance, EU funds, Data IP and Privacy, Life Sciences, Transport and Court of Justice of the European Union news.

The aim is to provide an up–to–date tool for quick and easy consultation on the most current and important topics at EU level.

EUROPEAN COMMISSION (EC)

The European Commission sends Statement of Objections to Alchem over first pharmaceutical cartel case in the EU (13.06.2024) – The European Commission has informed Alchem International Pvt. Ltd. and its subsidiary Alchem International (H.K.) Limited (together ‘Alchem') of its preliminary view that they have breached EU antitrust rules by participating in a long-lasting cartel concerning an important pharmaceutical product. Alchem is a producer of the pharmaceutical ingredient N-Butylbromide Scopolamine/Hyoscine (‘SNBB'). The Commission has concerns that Alchem may have coordinated and agreed with other market participants to fix the minimum sales price of SNBB to customers (i.e., distributors and generic drug manufacturers) and to allocate quotas. In addition, Alchem may have exchanged commercially sensitive information with competitors. In October 2023, the Commission adopted a settlement decision in relation to the same cartel and concerning other companies.

COUNCIL OF THE EUROPEAN UNION (COUNCIL)

Radioisotopes for medical use: the Council adopts its conclusion (17.06.2024) – The Council of the EU has endorsed its conclusions to secure the supply of radioisotopes for medical use as part of the Belgian presidency's priorities. Reiterating the critical role of radioisotopes for medical use in the diagnosis of cancer, heart conditions and other diseases, Council’s conclusions call on the European Commission to act on five key pillars: (i) Europe's global leadership role in the supply of radioisotopes for medical use, making tangible and rapid progress on the relevant actions identified; (ii) The monitoring and forecasting of demand and supply of all relevant radioisotopes for medical use (iii) Research and innovation on topics related to radioisotopes for medical use and other medical-radiological technologies (iv) The evaluation and development of critical skills (v) The evaluation of the framework for the transport of radioisotopes for medical use to help ensure access by patients in all member states. The Council also urges the European Medicines Regulatory Network to review all radiopharmaceuticals authorized in Europe and assess their criticality according to the existing methodology. Finally, the conclusions emphasize the important contribution of European research nuclear reactors and other nuclear facilities capable of producing radioisotopes for medical use at the levels needed to meet long-term needs in the Union, and the importance of these facilities, as well as the expertise that enables the production of these radioisotopes, continuing to be located in the European Union.


EUROPEAN MEDICINES AGENCY (EMA)

Faster access to clinical trial information in Europe (18.06.2024) – The launch of a new version of the Clinical Trials Information System (CTIS) will allow earlier and more efficient access to information about clinical trials in the European Union (EU) for patients, healthcare professionals and other stakeholders. This is due to the revised transparency rules that become applicable on 18th June 2024 in Europe.

Keep in touch!

Sign up for our newsletters!

Stay up-to-date on domestic and international legislative and tax news
and international, as well as all the Firm’s events and initiatives.

Back
to top